Abstract
No public abstract is available from the verified source records.
Yiren Su, Zhizhan Ni, Yujia Lu, Jianfei Huang, Jiebang Jiang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
10.1038/s41575-019-0189-8 · 2019
Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2021
Diagnosis and treatment of metastatic colorectal cancer: a review
10.1001/jama.2021.0106 · 2021
The genomic landscapes of human breast and colorectal cancers
10.1126/science.1145720 · 2007
Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review
10.1001/jamaoncol.2016.0405 · 2016
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
10.1038/s41467-018-08115-8 · 2019
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
10.1038/s41568-021-00375-9 · 2021
MEK inhibitor resistance mechanisms and recent developments in combination trials
10.1016/j.ctrv.2020.102137 · 2021
The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines
10.1007/s13277-015-3671-0 · 2015
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
10.1186/s12943-022-01629-2 · 2022
Therapeutic strategies to target RAS-mutant cancers
10.1038/s41571-018-0105-0 · 2018
Sotorasib for lung cancers with KRAS p.G12C mutation
10.1056/nejmoa2103695 · 2021
Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation
10.1056/nejmoa2204619 · 2022
Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal Cancer: a systematic literature review
10.1093/oncolo/oyad138 · 2023
Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
10.1016/s1470-2045(21)00605-7 · 2022
Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C
10.1056/nejmoa2212419 · 2023
Metabolic reprogramming and cancer progression
10.1126/science.aaw5473 · 2020
STAT proteins in cancer: orchestration of metabolism
10.1038/s41568-022-00537-3 · 2023
Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling
10.1186/s13046-019-1418-2 · 2019
RNA N(6)-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m(6)A-GLUT1-mTORC1 axis and is a therapeutic target
10.1053/j.gastro.2020.11.013 · 2021
Lycorine promotes IDH1 acetylation to induce mitochondrial dynamics imbalance in colorectal cancer cells
10.1016/j.canlet.2023.216364 · 2023
Enhanced De novo lipid synthesis mediated by FASN induces Chemoresistance in colorectal Cancer
10.3390/cancers15030562 · 2023
KRAS4A directly regulates hexokinase 1
10.1038/s41586-019-1832-9 · 2019
Slow TCA flux and ATP production in primary solid tumours but not metastases
10.1038/s41586-022-05661-6 · 2023
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
10.1038/s41588-020-00753-3 · 2021
The colorectal cancer lipidome: identification of a robust tumor-specific lipid species signature
10.1053/j.gastro.2021.05.009 · 2021
Methionine salvage and S-adenosylmethionine: essential links between sulfur, ethylene and polyamine biosynthesis
10.1042/bj20121744 · 2013
MSR1 characterized by chromatin accessibility mediates M2 macrophage polarization to promote gastric cancer progression
10.1016/j.intimp.2022.109217 · 2022
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
10.1101/gad.293449.116 · 2017
HIF-1alpha switches the functionality of TGF-beta signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer
10.1186/s13046-021-02188-y · 2021
Advancements in gene therapies targeting mutant KRAS in cancers
10.1007/s10555-025-10243-9 · 2025
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
10.1186/s12943-024-02218-1 · 2025
H2S-activated ion-interference therapy: a novel tumor targeted therapy based on copper-overload-mediated cuproptosis and pyroptosis
2023
Tumor-promoting properties of enolase-phosphatase 1 in breast cancer via activating the NF-kappaB signaling pathway
10.1007/s11033-022-08066-w · 2023
Enolase-phosphatase 1 acts as an oncogenic driver in glioma
10.1002/jcp.29926 · 2021
Human acireductone dioxygenase (HsARD), cancer and human health: black hat, white hat or gray?
2019
Regulation and signaling of TGF-beta autoinduction
2021
Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells
10.1016/s0021-9258(18)68561-8 · 1988
Transforming growth factor-beta signaling pathway in colorectal Cancer and its tumor microenvironment
10.3390/ijms20235822 · 2019
The two faces of transforming growth factor beta in carcinogenesis
10.1073/pnas.1633291100 · 2003
RAS-targeted cancer therapy: advances in drugging specific mutations
10.1002/mco2.285 · doi-reference
Wnt/snail signaling regulates cytochrome C oxidase and glucose metabolism
10.1158/0008-5472.can-12-0006 · doi-reference
Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer
10.1016/j.ccr.2013.01.022 · doi-reference
Metabolic dependencies in RAS-driven cancers
10.1158/1078-0432.ccr-14-2425 · doi-reference
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer
10.1038/nrc1208 · doi-reference